Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/302% above fair value
$64.63−1.20 (-1.82%)
Close on Nov 20, 2026Market cap $15.77BP/E 19.4Yield –
Exelixis gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Exelixis's gross profit for the twelve months ending Oct 2, 2026 was $2.40B, up 8.7% year over year. For fiscal 2025 it was $2.24B, up 6.9% from the year before. Over ten years it grew 52.3% a year on average. The highest annual figure on record is $2.24B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.24B | +6.9% |
| FY2024 | Jan 3, 2025 | $2.09B | +19.0% |
| FY2023 | Dec 29, 2023 | $1.76B | +13.2% |
| FY2022 | Dec 30, 2022 | $1.55B | +12.4% |
| FY2021 | Dec 31, 2021 | $1.38B | +45.3% |
| FY2020 | Jan 1, 2021 | $951.27M | +1.8% |
| FY2019 | Jan 3, 2020 | $934.68M | +13.0% |
| FY2018 | Dec 28, 2018 | $827.48M | +89.2% |
| FY2017 | Dec 29, 2017 | $437.41M | +136.6% |
| FY2016 | Dec 31, 2016 | $184.90M | +455.6% |
| FY2015 | Dec 31, 2015 | $33.28M | +44.3% |
| FY2014 | Dec 31, 2014 | $23.07M | -23.7% |
| FY2013 | Dec 31, 2013 | $30.22M | -36.3% |
| FY2012 | Dec 31, 2012 | $47.45M | -83.6% |
| FY2011 | Dec 31, 2011 | $289.64M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $632.46M | +9.2% |
| Q2 FY2026 | Jul 3, 2026 | $608.03M | +10.8% |
| Q1 FY2026 | Apr 3, 2026 | $590.86M | +10.2% |
| Q4 FY2025 | Jan 2, 2026 | $572.18M | +4.6% |
| Q3 FY2025 | Oct 3, 2025 | $579.18M | +10.9% |
| Q2 FY2025 | Jul 4, 2025 | $548.79M | -11.4% |
| Q1 FY2025 | Apr 4, 2025 | $536.28M | +32.8% |
| Q4 FY2024 | Jan 3, 2025 | $546.79M | +19.4% |
| Q3 FY2024 | Sep 27, 2024 | $522.21M | +15.2% |
| Q2 FY2024 | Jun 28, 2024 | $619.51M | +37.0% |
| Q1 FY2024 | Mar 29, 2024 | $403.97M | +2.4% |
| Q4 FY2023 | Dec 29, 2023 | $457.90M | +12.2% |
| Q3 FY2023 | Sep 29, 2023 | $453.15M | +14.3% |
| Q2 FY2023 | Jun 30, 2023 | $452.14M | +11.4% |
| Q1 FY2023 | Mar 31, 2023 | $394.47M | +15.1% |
| Q4 FY2022 | Dec 30, 2022 | $408.00M | -6.9% |
| Q3 FY2022 | Sep 30, 2022 | $396.43M | +25.2% |
| Q2 FY2022 | Jul 1, 2022 | $405.95M | +9.6% |
| Q1 FY2022 | Apr 1, 2022 | $342.78M | +33.4% |
| Q4 FY2021 | Dec 31, 2021 | $438.22M | +129.1% |
| Q3 FY2021 | Oct 1, 2021 | $316.55M | +98.0% |
| Q2 FY2021 | Jul 2, 2021 | $370.29M | +118.5% |
| Q1 FY2021 | Apr 2, 2021 | $257.03M | +39.2% |
| Q4 FY2020 | Jan 1, 2021 | $191.32M | +3.7% |
| Q3 FY2020 | Oct 2, 2020 | $159.86M | -13.2% |
| Q2 FY2020 | Jul 3, 2020 | $169.51M | -8.9% |
| Q1 FY2020 | Apr 3, 2020 | $184.59M | +7.3% |
| Q4 FY2019 | Jan 3, 2020 | $184.41M | +9.2% |
| Q3 FY2019 | Sep 27, 2019 | $184.23M | +18.4% |
| Q2 FY2019 | Jun 28, 2019 | $186.14M | +33.1% |
| Q1 FY2019 | Mar 29, 2019 | $172.08M | +33.8% |
| Q4 FY2018 | Dec 28, 2018 | $168.87M | +84.5% |
| Q3 FY2018 | Sep 28, 2018 | $155.59M | +69.6% |
| Q2 FY2018 | Jun 29, 2018 | $139.84M | +64.5% |
| Q1 FY2018 | Mar 30, 2018 | $128.63M | +95.9% |
| Q4 FY2017 | Dec 29, 2017 | $91.52M | +82.8% |
| Q3 FY2017 | Sep 30, 2017 | $91.76M | – |
| Q2 FY2017 | Jun 30, 2017 | $84.99M | – |
| Q1 FY2017 | Mar 31, 2017 | $65.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $50.06M | – |
See a number that looks wrong?